The study aimed to compare treatment retention for first-line TNF inhibitor (TNFi) in the ATTRA registry patients receiving either combination with conventional synthetic DMARDs or TNFi as monotherapy. A retrospective multicenter study analyzed data of all adult patients with rheumatoid arthritis (n = 3032) starting TNF inhibitor as the first-line biological therapy in combination with csDMARDs or in monotherapy from January 1st 2012 to December 31st 2020. Kaplan-Meier method was employed to calculate drug retentions. Survival curves of treatment retentions were compared through Log-rank test between the studied subgroups. The hazard ratio for drug discontinuation was assessed through univariate cox regression models. In patients who started the first line TNFi therapy, the median treatment retention was 47.7 (42.2; 53.1) months for combination therapy and 22.7 (14.9; 30.6) months for TNFi monotherapy (p < 0.001). Estimated one-year survival was higher in patients on TNFi combined with csDMARDs as compared with TNFi monotherapy (75.3% vs 65.7%); two-year survival rate was 63.2% vs 49.2%, three-year survival rate was 55.4% vs 42.4% and five-year survival 44.9% vs 26.4% of patients. The estimated survival on the first TNFi was higher in patients taking combination therapy with methotrexate than with other csDMARDs (p = 0.003). Use of csDMARDs co-medication was associated with significantly better first TNFi drug survival compared to monotherapy. The combination of TNFi with MTX is more effective than the combination with leflunomide, which did not demonstrate a significant effect.

3rd Department of Internal Medicine Nephrology Rheumatology and Endrocrinology Olomouc University Hospital 1 P Pavlova 6 77900 Olomouc Czech Republic

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Faculty of Medicine and Dentistry Palacký University Olomouc 1 P Pavlova 6 77900 Olomouc Czech Republic

Institute of Biostatistics and Analyses Ltd Brno Czech Republic

Zobrazit více v PubMed

Smolen J, Landewé R, Bijslma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699. doi: 10.1136/annrheumdis-2019-216655. PubMed DOI

Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology. 2000;39:655–665. doi: 10.1093/rheumatology/39.6.655. PubMed DOI

Weinblatt ME, Kaplan H, Germain BF, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. Arthritis Rheum. 1990;33:330–338. doi: 10.1002/art.1780330305. PubMed DOI

Jeurissen ME, Boerbooms AM, Van De Putte LB, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. a forty-eight-week randomized, double-blind trial. Arthritis Rheum. 1991;34:961–972. doi: 10.1002/art.1780340805. PubMed DOI

Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol. 2002;29:1631–1638. PubMed

Braun J. Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2011;3:151–158. doi: 10.1177/1759720X11408635. PubMed DOI PMC

Lipsky PE, Van Der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000;343:1594–1602. doi: 10.1056/NEJM200011303432202. PubMed DOI

Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213–222. doi: 10.1093/rheumatology/ket260. PubMed DOI PMC

Furst D, Breedveld FC, Kalden JR, et al. Updated consensed statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis. 2003;62(Suppl II):ii2–ii19. doi: 10.1136/ard.62.suppl_2.ii2. PubMed DOI PMC

Klarskog L, Van Der Heijde D, De Jager JP, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–681. doi: 10.1016/S0140-6736(04)15640-7. PubMed DOI

Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–382. doi: 10.1016/S0140-6736(08)61000-4. PubMed DOI

Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71:374–377. doi: 10.1136/annrheumdis-2011-200003. PubMed DOI

Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:583–589. doi: 10.1136/ard.2010.139774. PubMed DOI PMC

Favalli EG, Pregnolato F, Biggioggero M, et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res. 2016;68:432–439. doi: 10.1002/acr.22788. PubMed DOI

Ramiro S, Landewé R, Van Der Heijde D, et al. Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? RMD Open. 2015;1:e000155. doi: 10.1136/rmdopen-2015-000155. PubMed DOI PMC

Manders SH, Kievit W, Jansen TL, et al. Effectiveness of tumor necrosis factor inhibitors in combination with various csDMARD in the treatment of rheumatoid arthritis: data from the DREAM registry. J Rheumatol. 2016;43:1787–1794. doi: 10.1136/ard.2010.139774. PubMed DOI

Ebina K, Hashimoto M, Yamamoto W, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. PLoS ONE. 2018;13:e0194130. doi: 10.1371/journal.pone.0194130. PubMed DOI PMC

Martínez-Feito A, Plasenci-Rodríguez C, Navarro-Compán V, et al. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol. 2019;38:949–954. doi: 10.1007/s10067-018-4355-0. PubMed DOI

Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 2016;55:523–534. doi: 10.1093/rheumatology/kev374. PubMed DOI

Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72:1897–1904. doi: 10.1136/bmj.i1777. PubMed DOI PMC

Šenolt L, Mann H, Závada J, et al. Doporučení České revmatologické společnosti pro farmakologickou léčbu revmatoidní artritidy 2017. Čes Revmatol. 2017;25:8–24.

Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007;46:1140–1147. doi: 10.1093/rheumatology/kem072. PubMed DOI

Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:1786–1794. doi: 10.1002/art.21830. PubMed DOI

Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61:793–798. doi: 10.1136/ard.61.9.793. PubMed DOI PMC

Papadopoulos CG, Gartzonikas IK, Pappa TK, et al. Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry. Rheumatol Adv Pract. 2019;3:rkz007. doi: 10.1093/rap/rkz007. PubMed DOI PMC

Aaltonen KJ, Joensuu JT, Pirilä L, et al. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol. 2017;46:359–363. doi: 10.1080/03009742.2016.1234641. PubMed DOI

Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39:1179–1184. doi: 10.3899/jrheum.111125. PubMed DOI

Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:174. doi: 10.1186/ar2084. PubMed DOI PMC

Hansen KE, Cush J, Singhal A, Cooley DA, et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum. 2004;51:228–232. doi: 10.1002/art.20228. PubMed DOI

Perdriger A, Mariette X, Kuntz JL, et al. Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. J Rheumatol. 2006;33:865–869. PubMed

De Stefano R, Frati E, Nargi F, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate anti- TNF-alpha. Clin Rheumatol. 2010;29:517–524. doi: 10.1007/s10067-009-1349-y. PubMed DOI

Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2009;68:33–39. doi: 10.1136/ard.2007.085696. PubMed DOI

Strangfeld A, Hierse F, Kekow J, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856–1862. doi: 10.1136/ard.2008.098467. PubMed DOI

Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43:447–457. doi: 10.1016/j.semarthrit.2013.07.011. PubMed DOI

Choy E, Aletaha D, Behrens F, et al. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology (Oxford) 2017;56:689–697. doi: 10.1093/rheumatology/kew271. PubMed DOI

Mease PJ, Stryker S, Liu M, et al. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. Arthritis Res Ther. 2021;23:236. doi: 10.1186/s13075-021-02599-4. PubMed DOI PMC

Black RJ, Lester S, Buchbinder R, et al. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res Ther. 2017;19:253. doi: 10.1186/s13075-017-1461-3. PubMed DOI PMC

Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020 doi: 10.1136/rmdopen-2017-000536. PubMed DOI PMC

Cutolo M, Paolino S, Gotelli E. Glucocorticoids in rheumatoid arthritis still on first line: the reasons. Expert Rev Clin Immunol. 2021;5:417–420. doi: 10.1080/1744666X.2021.1903319. PubMed DOI

Hartman L, Rasch LA, Klausch T, et al. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. Trials. 2018;19:67. doi: 10.1186/s13063-017-2396-3. PubMed DOI PMC

Machine learning-assisted screening of clinical features for predicting difficult-to-treat rheumatoid arthritis